Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(15)
•••
Comment by PinnacleXon Aug 12, 2019 10:57am
126 Views
Post# 30017873

RE:RE:RE:RE:RE:RE:RE:RE:RE:Nasdaq Listing announcements

RE:RE:RE:RE:RE:RE:RE:RE:RE:Nasdaq Listing announcements
SPCEO1 wrote: Listing on NASDAQ kinda indicates theere are pretty cofnident about their future, don't you think???

PinnacleX wrote:
this once again shows the incompetance of this company. Terrible timing and a 100000$ usd they could have spent on something else instead of the fees associated with a Nasdaq listing. They are already bleeding money




Not saying they are not. JUST NOT NOW Nasdaq listing is a must but these patient numbers and sales have to increase. Nasdaq algos will RIP it apart after they see the financials as we are seeing today. You list on Nasdaq when you have good numbers it's always best. Now they are just paying fees on both exchanges . Ebit line is bad and liabilities due are way more then they have.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities